Richard Julian Jones
#155,285
Most Influential Person Now
Richard Julian Jones's AcademicInfluence.com Rankings
Richard Julian Jonesmedical Degrees
Medical
#3035
World Rank
#3486
Historical Rank
Hematology
#47
World Rank
#53
Historical Rank
Richard Julian Jonesbiology Degrees
Biology
#11923
World Rank
#15358
Historical Rank
Immunology
#785
World Rank
#808
Historical Rank
Neuroscience
#1970
World Rank
#2026
Historical Rank
Download Badge
Medical Biology
Richard Julian Jones's Degrees
- Doctorate Medicine Johns Hopkins University
- PhD Immunology Johns Hopkins University
Why Is Richard Julian Jones Influential?
(Suggest an Edit or Addition)Richard Julian Jones's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. (2008) (1386)
- VENOOCCLUSIVE DISEASE OF THE LIVER FOLLOWING BONE MARROW TRANSPLANTATION (1987) (820)
- Characterization of clonogenic multiple myeloma cells. (2004) (805)
- Cyclophosphamide and cancer: golden anniversary (2009) (627)
- Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. (2008) (543)
- Separation of pluripotent haematopoietic stem cells from spleen colony-forming cells (1990) (425)
- HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. (2012) (367)
- High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. (2010) (320)
- Association of Foxp3 regulatory gene expression with graft-versus-host disease. (2004) (313)
- Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation (2004) (266)
- Aldehyde Dehydrogenase Expression Drives Human Regulatory T Cell Resistance to Posttransplantation Cyclophosphamide (2013) (263)
- Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. (2008) (259)
- Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. (2003) (257)
- Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. (2010) (251)
- Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. (2015) (245)
- Immunoablative High-Dose Cyclophosphamide without Stem-Cell Rescue for Refractory, Severe Autoimmune Disease (1998) (236)
- Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. (2004) (221)
- Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. (2014) (207)
- A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. (2012) (206)
- INDUCTION OF GRAFT-VERSUS-HOST DISEASE AFTER AUTOLOGOUS BONE MARROW TRANSPLANTATION (1989) (203)
- Novel Oligoamine Analogues Inhibit Lysine-Specific Demethylase 1 and Induce Reexpression of Epigenetically Silenced Genes (2009) (196)
- Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. (2015) (192)
- Cancer stem cells: are we missing the target? (2004) (182)
- A Prospective Pharmacologic Evaluation of Age-Related Toxicity of Adjuvant Chemotherapy in Women with Breast Cancer (2000) (177)
- Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. (2010) (174)
- Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. (2012) (172)
- Selective radiosensitization of p53–deficient cells by caffeine–mediated activation of p34cdc2 kinase (1996) (172)
- A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. (2015) (167)
- Circulating clonotypic B cells in classic Hodgkin lymphoma. (2009) (167)
- Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. (2014) (152)
- The paradox of response and survival in cancer therapeutics. (2006) (151)
- Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. (2011) (145)
- High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. (2003) (145)
- Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide (2017) (142)
- Autologous bone marrow transplantation (1993) (135)
- CFU-GM content of bone marrow graft correlates with time to hematologic reconstitution following autologous bone marrow transplantation with 4- hydroperoxycyclophosphamide-purged bone marrow (1987) (132)
- Treatment of refractory myasthenia: “Rebooting” with high‐dose cyclophosphamide (2003) (129)
- Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduce (2019) (127)
- Regulation of human hematopoietic stem cell self-renewal by the microenvironment’s control of retinoic acid signaling (2013) (126)
- Pancreatic Lymphoma. Is Surgery Mandatory for Diagnosis or Treatment? (1989) (125)
- PIG-A mutations in normal hematopoiesis. (2004) (122)
- Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma (2015) (115)
- The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. (2008) (111)
- Two Phases of Engraftment Established by Serial Bone Marrow Transplantation in Mice (1989) (111)
- High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. (2002) (107)
- Durable Treatment-Free Remission after High-Dose Cyclophosphamide Therapy for Previously Untreated Severe Aplastic Anemia (2001) (107)
- Multilineage glycosylphosphatidylinositol anchor‐deficient haematopoiesis in untreated aplastic anaemia (2001) (104)
- High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. (2010) (104)
- Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies. (2013) (101)
- Rebooting the Immune System with High‐Dose Cyclophosphamide for Treatment of Refractory Myasthenia Gravis (2008) (98)
- K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate (2010) (97)
- Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors (2005) (95)
- Characterization of chronic myeloid leukemia stem cells (2011) (95)
- Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. (2007) (94)
- Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. (2013) (94)
- HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. (2014) (92)
- Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations (2013) (91)
- High-dose cyclophosphamide for graft-versus-host disease prevention (2010) (90)
- Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia. (2017) (89)
- Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial. (2019) (89)
- Telomerase Inhibition Targets Clonogenic Multiple Myeloma Cells through Telomere Length-Dependent and Independent Mechanisms (2010) (86)
- Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. (2008) (85)
- Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. (2013) (84)
- PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model (2016) (84)
- Sequential Flavopiridol, Cytosine Arabinoside, and Mitoxantrone: A Phase II Trial in Adults with Poor-Risk Acute Myelogenous Leukemia (2007) (82)
- Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide (2011) (82)
- A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. (2014) (81)
- Concise Review: Cancer Stem Cells and Minimal Residual Disease (2012) (78)
- Aplastic anaemia (2005) (78)
- Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide. (2017) (74)
- Identification of Novel p53 Pathway Activating Small-Molecule Compounds Reveals Unexpected Similarities with Known Therapeutic Agents (2010) (74)
- Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. (2010) (72)
- Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. (2012) (70)
- Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. (2020) (68)
- Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation (2016) (66)
- Targeting SQSTM1/p62 Induces Cargo Loading Failure and Converts Autophagy to Apoptosis via NBK/Bik (2014) (62)
- Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning. (2009) (62)
- Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide. (2018) (61)
- Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia (1994) (60)
- Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. (2017) (59)
- Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies. (2017) (57)
- ZEB1 and c-Jun Levels Contribute to the Establishment of Highly Lytic Epstein-Barr Virus Infection in Gastric AGS Cells (2007) (57)
- Epstein-Barr virus-specific methylation of human genes in gastric cancer cells (2010) (57)
- 5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation. (2011) (57)
- All-Trans Retinoic Acid Activity in Acute Myeloid Leukemia: Role of Cytochrome P450 Enzyme Expression by the Microenvironment (2015) (56)
- Strategies to eliminate cancer stem cells: clinical implications. (2006) (54)
- Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors. (2018) (52)
- Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. (2006) (52)
- Mutual Exclusivity of MED12/MED12L, MED13/13L, and CDK8/19Paralogs Revealed within the CDK-Mediator Kinase Module (2013) (50)
- Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA (2012) (50)
- Inhibited apoptosis and drug resistance in acute myeloid leukaemia (1998) (47)
- Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma. (2005) (47)
- Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. (2021) (46)
- Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma. (2006) (45)
- High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial. (2010) (45)
- Anti‐tumour activity of interferon‐alpha in multiple myeloma: role of interleukin 6 and tumor cell differentiation (2003) (44)
- Double unrelated umbilical cord blood versus HLA-haploidentical bone marrow transplantation (BMT CTN 1101). (2020) (42)
- Pluripotent Stem Cell–Based Cancer Therapy: Promise and Challenges (2012) (42)
- Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma. (2019) (41)
- Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. (2018) (40)
- Human bone marrow niche chemoprotection mediated by cytochrome p450 enzymes (2015) (40)
- Epstein-Barr Virus Lytic Infection Induces Retinoic Acid-responsive Genes through Induction of a Retinol-metabolizing Enzyme, DHRS9* (2007) (39)
- HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma. (2011) (39)
- Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. (2018) (39)
- Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein–Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression (2016) (38)
- Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors. (2019) (37)
- Phenotypic and functional characterization of the hematopoietic stem cell (1997) (37)
- Glycosylphosphatidylinositol-anchored protein deficiency confers resistance to apoptosis in PNH. (2009) (37)
- In utero hematopoietic stem cell transplantation with haploidentical donor adult bone marrow in a canine model. (2004) (37)
- Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation. (2017) (37)
- High-dose cyclophosphamide as salvage therapy for severe aplastic anemia. (2004) (37)
- Severe cytokine release syndrome after haploidentical peripheral blood transplantation. (2019) (36)
- Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation (2021) (36)
- Inhibition of the p53 E3 Ligase HDM-2 Induces Apoptosis and DNA Damage–Independent p53 Phosphorylation in Mantle Cell Lymphoma (2008) (35)
- Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance. (2016) (35)
- All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo. (2016) (35)
- Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells. (2003) (34)
- High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement. (2005) (34)
- The role of growth factors in the activity of pharmacological differentiation agents. (2002) (34)
- High-Dose Cyclophosphamide Without Stem Cell Rescue in 207 Patients With Aplastic Anemia and Other Autoimmune Diseases (2011) (34)
- Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant (2004) (34)
- Prospective Study of Peri-Transplant Use of Sorafenib As Remission Maintenance for FLT3-ITD Patients Undergoing Allogeneic Transplantation (2015) (33)
- Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide. (2019) (31)
- Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma (2018) (30)
- Characterization of aldehyde dehydrogenase 1 high ovarian cancer cells: Towards targeted stem cell therapy. (2016) (30)
- FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical? (2019) (29)
- New Developments in the Therapy of Acute Myelocytic Leukemia. (2000) (28)
- Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia (2005) (28)
- Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. (2020) (28)
- Inhibition of the MDM2 E3 Ligase Induces Apoptosis and Autophagy in Wild-Type and Mutant p53 Models of Multiple Myeloma, and Acts Synergistically with ABT-737 (2014) (28)
- Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies. (2017) (27)
- Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes. (2018) (27)
- A prospective study of peri-transplant sorafenib for FLT3-ITD AML patients undergoing allogeneic transplantation. (2020) (26)
- Cancer Stem Cells: From Bench to Bedside. (2007) (26)
- Treatment of relapsing–remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance (2012) (25)
- Signatures of GVHD and Relapse after Post-Transplant Cyclophosphamide Revealed by Immune Profiling and Machine Learning. (2021) (25)
- ELIMINATION OF ALLOANTIBODIES BY IMMUNOABLATIVE HIGH-DOSE CYCLOPHOSPHAMIDE 1 (2001) (24)
- Cancer stem cells—clinical relevance (2009) (24)
- Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. (2007) (24)
- Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors. (2015) (24)
- Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. (2018) (24)
- Repeated treatment with high dose cyclophosphamide for severe autoimmune diseases. (2013) (23)
- Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia (2015) (23)
- Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor–Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies (2021) (23)
- Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide. (2021) (23)
- The Novel Anticancer Agent JNJ-26854165 Induces Cell Death through Inhibition of Cholesterol Transport and Degradation of ABCA1 (2013) (22)
- Allogeneic hematopoietic cell transplant for HIV patients with hematologic malignancies: the BMT CTN-0903/AMC-080 trial. (2019) (22)
- The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia. (2012) (22)
- Silencing of genes required for glycosylphosphatidylinositol anchor biosynthesis in Burkitt lymphoma. (2009) (21)
- Retinoic acid, CYP26, and drug resistance in the stem cell niche. (2017) (21)
- Checkpoint Inhibitor Therapy and Graft Versus Host Disease in Allogeneic Bone Marrow Transplant Recipients of Haploidentical and Matched Products with Post-Transplant Cyclophosphamide. (2016) (21)
- Association of acute myeloid leukemia’s most immature phenotype with risk groups and outcomes (2016) (21)
- Radiobiologic Optimization of Combination Radiopharmaceutical Therapy Applied to Myeloablative Treatment of Non-Hodgkin Lymphoma (2013) (20)
- High-dose cyclophosphamide in aplastic anaemia (2001) (20)
- The evolution of treatment strategies for patients with chronic myeloid leukemia relapsing after allogeneic bone marrow transplant: can tyrosine kinase inhibitors replace donor lymphocyte infusions? (2015) (20)
- Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy. (2017) (19)
- Environmental pollutant induced cellular injury is reflected in exosomes from placental explants. (2020) (19)
- Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support. (2006) (19)
- HDP101, a Novel B-Cell Maturation Antigen (BCMA)-Targeted Antibody Conjugated to α-Amanitin, Is Active Against Myeloma with Preferential Efficacy Against Pre-Clinical Models of Deletion 17p (2018) (18)
- Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide. (2020) (18)
- Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF. (2011) (18)
- 6: Post-transplantation high-dose cyclophosphamide (Cy) is effective single agent GVHD prophylaxis that permits prompt immune reconstitution after myeloablative HLA matched related and unrelated bone marrow transplantation (BMT) (2007) (18)
- Intraductally administered pegylated liposomal doxorubicin reduces mammary stem cell function in the mammary gland but in the long term, induces malignant tumors (2012) (18)
- Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: a Retrospective Cohort Study. (2020) (18)
- Intensive immunosuppression with high dose cyclophosphamide but without stem cell rescue for severe autoimmunity: Advantages and disadvantages (2008) (17)
- Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions (2015) (17)
- Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients. (2017) (17)
- Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia (2011) (17)
- Epstein-Barr virus nuclear antigen 1 (EBNA1) induced cytotoxicity in epithelial cells is associated with EBNA1 degradation and processing. (2003) (17)
- Eculizumab Bridging before Bone Marrow Transplant for Marrow Failure Disorders Is Safe and Does Not Limit Engraftment. (2018) (16)
- Chondroitin sulfate proteoglycan serglycin influences protein cargo loading and functions of tumor-derived exosomes (2017) (16)
- Use of T-Cell Antibodies for Donor Dosaging in a Canine Model of in utero Hematopoietic Stem Cell Transplantation (2007) (16)
- Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. (2008) (16)
- Autologous bone marrow transplantation with 4‐hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10‐year experience (2002) (15)
- Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia (2013) (15)
- Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma. (2011) (14)
- Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide (2016) (14)
- Myeloablative Haploidentical Bone Marrow Transplantation with T Cell Replete Grafts and Post-Transplant Cyclophosphamide: Results of a Phase II Clinical Trial, (2011) (14)
- Haploidentical transplantation: repurposing cyclophosphamide. (2012) (14)
- Acute Myeloid Leukemia Stem Cell Heterogeneity and Its Clinical Relevance. (2019) (14)
- BCR-ABL Gene Rearrangement and Expression of Primitive Hematopoietic Progenitors in Chronic Myeloid Leukemia (1993) (14)
- Factors Affecting Topotecan Sensitivity in Human Leukemia Samples a (1996) (14)
- Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70. (2019) (13)
- Cancer stem cells: relevance to clinical transplantation (2012) (13)
- Gender‐related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes (2021) (13)
- Translating leukemia stem cells into the clinical setting: Harmonizing the heterogeneity. (2016) (13)
- Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703 (2022) (13)
- Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study (2021) (13)
- Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma. (2017) (13)
- Cancer stem cells in hematopoietic malignancies. (2008) (13)
- Implementing the Surviving Sepsis Campaign in an Ambulatory Clinic for Patients With Hematologic Malignancies. (2016) (13)
- R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma (2019) (13)
- Overcoming microenvironment-mediated protection from ATRA using CYP26-resistant retinoids (2020) (12)
- Cancer Stem Cells in Hematopoietic Malignancies. (2008) (12)
- Shortened-duration immunosuppressive therapy after nonmyeloablative, related HLA-haploidentical or unrelated peripheral blood grafts and post-transplantation cyclophosphamide. (2020) (12)
- Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention: A Review Part 1. (2019) (12)
- Reduced Intensity Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Pediatric Inherited Immune Deficiencies and Bone Marrow Failure Syndromes (2020) (11)
- Burst-forming unit-erythroid assays to distinguish cellular bone marrow failure disorders. (2013) (11)
- Clonotypic B Cells Circulate in Hodgkin’s Lymphoma (HL). (2006) (11)
- Correlation of clonogenic cancer stem cell (CSC) growth with clinical outcomes in multiple myeloma (MM) patients undergoing treatment with high dose cyclophosphamide (Cy) and rituximab (2008) (10)
- Sex-Related Differences in Chronic Myeloid Neoplasms: From the Clinical Observation to the Underlying Biology (2021) (10)
- Haploidentical BMT Using Fully Myeloablative Conditioning, T Cell Replete Bone Marrow Grafts, and Post-Transplant Cyclophosphamide (PT/Cy) Has Limited Toxicity and Promising Efficacy in Largest Reported Experience with High Risk Hematologic Malignancies (2015) (10)
- Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191 (2018) (10)
- High-dose Cyclophosphamide is Effective Therapy for Pediatric Severe Aplastic Anemia (2016) (10)
- Complete Remissions Post Infusion of Multiple Tumor Antigen Specific T Cells for the Treatment of High Risk Leukemia and Lymphoma Patients after HCT (2017) (10)
- Haplotype Counting for Sensitive Chimerism Testing: Potential for Early Leukemia Relapse Detection. (2017) (10)
- HDP-101, a Novel BCMA-targeted Antibody Conjugated to α-Amanitin, is Active against Myeloma with Preferential Efficacy against Pre-clinical Models of Deletion 17p (2019) (10)
- HLA-Haploidentical Bone Marrow Transplantation (BMT) for High Risk Hematologic Malignancies Using Myeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide (2010) (10)
- Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies. (2016) (10)
- Desensitization for Mismatched Hematopoietic Stem Cell Transplantation (HSCT) (2011) (10)
- Leukemic stem cells: where have they gone wrong? (2001) (9)
- Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study. (2020) (9)
- Double Cord Blood Transplantation (CBT) With Ex-Vivo Expansion (EXP) of One Unit Utilizing A Mesenchymal Stromal Cell (MSC) Platform (2009) (9)
- A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation (2020) (9)
- Post-Transplantation Cyclophosphamide (Cy) Reduces Graft Rejection and Graft-Versus-Host Disease (GVHD) after Non-Myeloablative, Partially HLA-Mismatched (Haploidentical) Bone Marrow Transplantation (BMT). (2004) (9)
- Comparable and Robust Immune Reconstitution after HLA-Haploidentical or HLA-Matched Allogeneic Transplantation (BMT) Utilizing Posttransplantation Cyclophosphamide (2015) (9)
- In utero Hematopoietic Stem Cell Transplantation in Canines: Exploring the Gestational Age Window of Opportunity to Maximize Engraftment (2013) (9)
- Identification and characterization of a spontaneous ovarian carcinoma in Lewis rats (2010) (8)
- Combination Therapy With Casirivimab/Imdevimab and Remdesivir for Protracted SARS-CoV-2 Infection in B-cell-Depleted Patients (2022) (8)
- Allogeneic Haploidentical Blood or Marrow Transplantation with Post-Transplant Cyclophosphamide in Chronic Lymphocytic Leukemia. (2019) (8)
- Umbilical cord blood or HLA-haploidentical transplantation: Real world outcomes vs randomized trial outcomes. (2021) (8)
- Human leukocyte antigen-haploidentical hematopoietic stem cell transplant for a patient with histiocytic sarcoma (2013) (8)
- Cesarean Section Incision Complications and Associated Risk Factors: A Quality Assurance Project (2015) (8)
- Antitumor Activity of Syngeneic/Autologous Graft‐versus‐Host Disease a (1995) (7)
- Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016. (2018) (7)
- High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas (2011) (7)
- Extended follow-up of autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide (4-HC) purging for indolent or transformed non-Hodgkin lymphomas. (2011) (7)
- Isolated clonal cytogenetic abnormalities after high-dose therapy. (2014) (7)
- Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes. (2020) (7)
- Genomic characterization of chromosome translocations in patients with T/myeloid mixed-phenotype acute leukemia (2018) (7)
- Multiple Myeloma Stem Cells and Plasma Cells Display Distinct Drug Sensitivities. (2004) (7)
- Regulation of drug metabolizing enzymes in the leukaemic bone marrow microenvironment (2019) (6)
- Significance of Missing Inhibitory KIR Ligands in Nonmyeloablative, HLA-Haploidentical (Haplo) BMT with Posttransplantation High-Dose Cyclophosphamide (PT/Cy) (2011) (6)
- Randomized Study of Double Cord Blood Transplantation (CBT) with Versus without Ex-Vivo Expansion (EXP). (2007) (6)
- DNMT3A clonal Hematopoiesis in Older Donors Is Associated with Improved Survival in Recipients after Allogeneic Hematopoietic Cell Transplant (2020) (6)
- Granulocyte-macrophage colony stimulating factor (GM-CSF) enhances the clinical responses to interferon-α (IFN) in newly diagnosed chronic myeloid leukemia (CML). (2014) (6)
- Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention: A Review Part 2. (2019) (6)
- Hematopoietic Cell Transplantation: Practice Predictions for the Year 2023 (2020) (6)
- Targeted pathologic evaluation of bone marrow donors identifies previously undiagnosed marrow abnormalities. (2013) (6)
- HLA-matching with PTCy: a reanalysis of a CIBMTR dataset with propensity score matching and donor age (2022) (5)
- High‐dose cyclophosphamide in severe aplastic anaemia (2004) (5)
- The Anti-Tumor Effect of the Ubiquitin-Activating Enzyme (UAE) Inhibitor TAK-243 on Pre-Clinical Models of Multiple Myeloma (2016) (5)
- Utilization of intensive care resources due to better communication of end-of-life issues. (2012) (5)
- Cancer Stem Cell Targeting in Multiple Myeloma by GRN163L, a Novel and Potent Telomerase Inhibitor. (2006) (5)
- Bone marrow transplantation for multiple myeloma: where we are today (2002) (5)
- Controversies in cancer stem cells (2009) (5)
- Outcomes Of Nonmyeloablative (NMA) Haploidentical Blood Or Marrow Transplantation (haploBMT) With High-Dose Posttransplantation Cyclophosphamide (PT/Cy) For Lymphoma (2013) (5)
- Pharmacology of Bone Marrow Transplantation Conditioning Regimens a (1995) (5)
- Epstein-Barr Virus WZhet DNA Can Induce Lytic Replication in Epithelial Cells in vitro, although WZhet Is Not Detectable in Many Human Tissues in vivo (2009) (5)
- Posttransplantation Cyclophosphamide-based Graft versus Host Disease Prophylaxis with Non-myeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis. (2022) (5)
- Thrombotic Microangiopathy After Post-Transplantation Cyclophosphamide-Based GVHD Prophylaxis. (2020) (5)
- 26: Genomic and proteomic investigation of preimplantation factor′s impact on human decidual cells (2009) (5)
- Phase I/II Study of Marrow Infiltrating Lymphocytes (MILs) Generates Measurable Myeloma-Specific Immunity in the Autologous Stem Cell Transplant (SCT) Setting (2011) (5)
- The Telomerase Inhibitor, Imetelstat, Rapidly Reduces Myeloma Cancer Stem Cells (CSCs) in a Phase II Trial (2012) (5)
- Related Nonmyeloablative Haploidentical (mini-haplo) Blood or Marrow Transplantation (BMT) with High-Dose Post-Transplant Cyclophosphmade (PTCy) for Acute Myeloid Leukemia (AML): Donor Age Impacts Outcome (2015) (4)
- Autologous graft-versus-host disease: immunotherapy of breast cancer after bone marrow transplantation (2004) (4)
- Nonmyeloablative HLA-Haploidentical BMT with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome (2010) (4)
- BMT CTN State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. (2021) (4)
- Inhibition of the Human Double Minute (HDM)-2 E3 Ubiquitin Ligase Activates Different Programmed Cell Death (PCD) Pathways in Models of Non-Hodgkin Lymphoma (NHL) with Wild Type (wt) and Mutant (mut) p53 (2008) (4)
- Improved Event-Free Survival and Higher Incidence of Early Fever Associated with Mismatches at HLA-DRB1 after Nonmyeloablative HLA-Haploidentical Transplantation (2017) (4)
- Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT (2022) (4)
- Bone Marrow Stroma Protects FLT3 Acute Myeloid Leukemia (AML) through CYP3A4-Mediated Drug Metabolization of FLT3 Tyrosine Kinase Inhibitors (TKIs) (2017) (4)
- Favorable Outcome of Patients with Relapsed Hodgkin Lymphoma (HL) after Nonmyeloablative Hematopoietic Cell Transplantation (NM-HCT) Using Related Haploidentical Donors. (2006) (4)
- Cytomegalovirus in Adult Allogeneic Blood and Marrow Transplant Patients Before or Around the Period of Neutrophil Recovery: A Single-Center, Retrospective, Descriptive Study (2020) (4)
- Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial. (2022) (4)
- Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy (2022) (4)
- Pain Experiences of Adults With Sickle Cell Disease and Hematopoietic Stem Cell Transplantation: A Qualitative Study. (2021) (4)
- Allogeneic Bone Marrow Transplantation, Zidovudine, and Human Immunodeficiency Virus Type 1 (HIV-I) Infection (2020) (4)
- Rarity of Donor-Derived Malignancy after Allogeneic BMT with High-Dose Post-Transplantation Cyclophosphamide (2014) (4)
- Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors (2020) (3)
- Stem cells. (2010) (3)
- Cytomegalovirus Reactivation in Haploidentical Blood or Marrow Transplant (BMT) Using Post-Transplant Cyclophosphamide (PTCy) Is Associated with Higher Non-Relapse-Related Mortality, Despite Rarity of Disease (2018) (3)
- Preclinical Development Drug Resistance to Inhibitors of the Human Double Minute-2 E 3 Ligase Is Mediated by Point Mutations of p 53 , but Can Be Overcome with the p 53 Targeting Agent RITA (2012) (3)
- Nonmyeloablative, HLA-mismatched unrelated peripheral blood transplantation with high-dose posttransplantation cyclophosphamide. (2021) (3)
- Patients with FLT3/ITD AML May Benefit From Allogeneic Transplant In First Remission: Outcomes From a Consecutive Series of Patients at a Single Institution (2010) (3)
- hematopoietic progenitors in chronic myeloid leukemia BCR-ABL gene rearrangement and expression of primitive (2011) (3)
- The Leukemic Stem Cell in Polycythemia Vera and Primary Myelofibrosis Is Distinct From the Initiating JAK2 V617F-Positive Hematopoiertic Stem Cell (2011) (3)
- Post-Transplantation Cyclophosphamide Following Busulfan and Fludarabine Myeloablative Conditioning Prevents Severe Acute and Chronic Graft-Versus-Host Disease and Minimizes Duration Of Immunosuppression: Results Of a Multi-Institutional Trial In Patients With High-Risk Hematologic Malignancies (2013) (3)
- Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation (haplo-BMT) With Post-Transplant High-Dose Cyclophosphamide (Cy) in Patients With Severe Hemoglobinopathies (2011) (3)
- Immune Reconstitution After Nonmyeloablative, T-Cell Replete, HLA-Haploidentical BMT With Post-Transplantation Cyclophosphamide (2011) (3)
- Shortened-Duration Tacrolimus after Nonmyeloablative HLA-Haploidentical (NMA haplo) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Facilitates Strategies for Relapse Reduction (2016) (3)
- Topoisomerase I 1 Levels and Drug Sensitivity in Adult Acute Myelogenous Leukemia (3)
- Haploidentical Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Myelofibrosis: A Multi-Institutional Experience (2020) (3)
- Gm-Csf Improves Activity of Interferon as Primary Therapy for CML. (2004) (3)
- Using Haploidentical (haplo) Donors and High-Dose Post-Transplant Cyclophosphamide (PTCy) for Refractory Severe Aplastic Anemia (SAA) (2015) (3)
- Should an HLA-matched donor still be considered the perfect donor? (2018) (3)
- High-dose cyclophosphamide as single agent, short-course prophylaxis of graft- (2017) (3)
- High-dose cyclophosphamide without stem cell rescue for the treatment of refractory Behcet's disease. (2011) (3)
- Hexaviral specific T-cells targeting parainfluenza, CMV, EBV, adenovirus, HHV6 and BKV used for prophylaxis and treatment of viral infections in patients post stem cell transplant (2019) (3)
- "Allogeneic blood or marrow transplant with non-myeloablative conditioning and high dose cyclophosphamide-based graft-versus-host disease prophylaxis for secondary central nervous system lymphoma". (2021) (3)
- High Dose Cyclophosphamide (CY) for Severe Aplastic Anemia (SAA): Safety and Long Term Follow-Up. (2005) (3)
- The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance (2020) (3)
- Greater HLA Disparity Is Associated with Reduced Risk of Relapse and Improved Event-Free Survival after Nonmyeloablative, HLA-Haploidentical BMT with Post-Transplantation High-Dose Cyclophosphamide (2008) (3)
- FLT3 Inhibition and Retinoid Signaling Overcome Stromal Protection to Target FLT3/ITD-Expressing Leukemia Stem Cells in the Bone Marrow Microenvironment (2015) (3)
- K562/GM-CSF Vaccination Reduces Tumor Burden, Including Achieving Molecular Remissions, in Chronic Myeloid Leukemia (CML) Patients with Residual Disease on Imatinib Mesylate (IM). (2005) (3)
- The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia (2021) (3)
- Graft-Versus-Host Disease (GVHD) and Survival Outcomes after HLA-Haploidentical (Haplo) Bone Marrow Transplant (BMT) Compare Favorably with Matched Related Donor (MRD), and Matched Unrelated Donor (MUD) BMT Utilizing High-Dose Posttransplantation Cyclophosphamide (PTCy) (2014) (3)
- Favorable Immune Reconstitution After Nonmyeloablative, T-Cell Replete, HLA-Haploidentical BMT with Post-Transplant Cyclophosphamide (2011) (3)
- Outcomes of Autologous and Allogeneic BMT for Mantle Cell Lymphoma. (2004) (3)
- A Novel Triple Purge Strategy for Eliminating Chronic Myelogenous Leukemia (CML) Cells from Autografts. (2004) (3)
- Impact of Killer Immunoglobulin Receptor (KIR) Ligand Incompatibility in Nonmyeloablative Bone Marrow Transplantation (BMT) from Haploidentical Donors. (2006) (3)
- A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) (2021) (3)
- The Clinical Relevance of Acute Myeloid Leukemia Stem Cells (2011) (3)
- The Path to Cure: Using Haploidentical (haplo) Donors and High-Dose Post-Transplant Cyclophosphamide (PTCy) for Treatment-Naïve and Refractory Severe Aplastic Anemia (SAA) (2019) (2)
- Nonmyeloablative (NMA), HLA-Mismatched Unrelated Donor (mMUD) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Has Outcomes Similar to Matched BMT (2015) (2)
- Thrombotic Microangiopathy after Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis (2020) (2)
- Results of Blood and Marrow Transplant Clinical Trials Network Protocol 1101 a Multicenter Phase III Randomized Trial of Transplantation of Double Umbilical Cord Blood Vs. HLA‐Haploidentical ‐Related Bone Marrow for Hematologic Malignancy (2020) (2)
- Nonmyeloablative HLA-Haploidentical (NMA Haplo) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Is Associated with Similar Outcomes to Matched BMT When Stratified By Disease Risk Index (DRI) (2014) (2)
- Thalidomide, Lenalidomide and Pomalidomide Disrupt Epstein-Barr Virus (EBV) Latency: Clinical Implications (2013) (2)
- Is It Time to Revisit the Role of Allogeneic Transplantation in Lymphoma? (2019) (2)
- Venous Thromboembolism among 1,570 Patients Undergoing Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment and Outcomes. (2007) (2)
- Encouraging Outcomes In Older Patients (Pts) Following Nonmyeloablative (NMA) Haploidentical Blood or Marrow Transplantation (haploBMT) With High-Dose Posttransplantation Cyclophosphamide (PT/Cy) (2013) (2)
- RNA Polymerase I Inhibition with CX-5461 As a Novel Strategy to Target MYC in Multiple Myeloma (2015) (2)
- A Novel Antibody Drug Conjugate (ADC) Targeting Cell Surface Heat Shock Protein 70 (csHSP70) Is Active Against Pre-Clinical Models of Peripheral T-Cell Lymphoma (PTCL) (2021) (2)
- Exosome targeted therapy—a step in the future (2017) (2)
- Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience. (2021) (2)
- Long-term follow-up of allogeneic marrow transplantation for acute myelogenous leukemia after treatment with busulfan and cyclophosphamide. (2006) (2)
- Risk-Adapted Therapy of Aggressive Lymphoma Based on FDG-PET Performed after 2 or 3 Cycles of Initial Chemotherapy. (2007) (2)
- Bone Marrow Niche - Multiple Myeloma Cross-Talk Generates Bortezomib Resistance (2015) (2)
- Stem Cell Transplantation for AML (2007) (2)
- Oral concurrent session 6Diabetes: Abstracts 62 – 7062: Hyperglycemia impairs cytotrophoblast function via stress signaling (2014) (2)
- The Anti-B-Cell Maturation Antigen (BCMA) Antibody-α-Amanitin Conjugate Hdp-101 Induces Immunogenic Cell Death and Immunologic Memory in Models of Multiple Myeloma (2020) (2)
- High-Dose Cyclophosphamide (Cy), Rituximab, and a Cancer Vaccine for Relapsed Classical Hodgkin's Lymphoma (cHL) (2010) (2)
- Dosing of Busulfan in Overweight and Obese Patients Compared to Normal Weight Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) (2012) (2)
- Differentiation Therapy for Poor Risk Myeloid Malignancies: Results of a Dose Finding Study of Bryostatin-1 (BRYO) + GM-CSF. (2005) (2)
- Post-transplantation Cyclophosphamide (Cy) as a single agent for GVHD prophylaxis after HLA matched related and unrelated bone marrow transplantation (2006) (2)
- A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML. (2021) (2)
- Post-Transplantation High Dose Cyclophosphamide (Cy) Is Effective Single Agent for Prevention of Acute and Chronic Graft Versus Host Disease after Myeloablative HLA Matched Related and Unrelated Bone Marrow Transplantation (BMT) (2008) (2)
- CD34+ cell of origin for immunoglobulin heavy chain variable region unmutated, but not mutated, chronic lymphocytic leukemia (2022) (2)
- A Phase 1 Study of IRX195183, a RARα-Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AML (2020) (2)
- A Phase IB Study of Blinatumomab (blina) in Patients with B Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (allo-BMT) Remission Maintenance (2019) (2)
- Significance of Haplotype B Donors and Gene Content Motifs in Nonmyeloablative, HLA-Haploidentical (Haplo) Bmt with Posttransplantation High-Dose Cyclophosphamide (PT/Cy) (2012) (2)
- Single Cell Analysis Of JAK2V617F Positive MPN Stem/Progenitor Cells In Chronic Phase and Leukemic Transformation (2013) (2)
- Outcomes of Allogeneic Blood or Marrow Transplantation for Peripheral T-Cell Lymphoma. (2012) (2)
- A Randomized Phase II Trial of Interferon (IFN)/GM-CSF Versus K562/GM-CSF Vaccination in Chronic Phase CML Patients on Frontline Tyrosine Kinase Inhibitor (TKI) Therapy: Potential of IFN to Enhance Molecular Remissions (2016) (1)
- Multi-institutional study of allogeneic bone marrow transplantation using myeloablative busulfan (Bu)/fludarabine (Flu) conditioning and short-course, single-agent graft-versus-host disease (GVHD) prophylaxis with high-dose, post-transplantation cyclophosphamide (PTCy). (2013) (1)
- Bone Marrow (BM) Stromal Expression Of Cytochrome P450 (CYP) Enzymes Protects Acute Myeloid Leukemia (AML) From All-Trans Retinoic Acid (atRA) (2013) (1)
- Shortened Immunosuppression Following Peripheral Blood (PB) Haploidentical (haplo) Transplantation with Post-Transplant Cyclophosphamide (PTCy) Is Associated with Tolerable Rates of Graft-Vs-Host Disease (GVHD) (2019) (1)
- Phase II Study of High Dose Outpatient Cyclophosphamide and Rituximab, without Stem Cell Support, for Low Grade and Mantle Cell Lymphoma. (2006) (1)
- Incidence of large granular lymphocytosis (LGL) in patients with late cytopenias after allogeneic blood or marrow transplantation (AlloBMT). (2020) (1)
- Blockade of IGF-1R with OSI-906 Overcomes Bortezomib-Resistance in Multiple Myeloma (2011) (1)
- Preparative regimens in bone marrow transplantation: An analysis of outcomes in 1174 patients (1998) (1)
- transplantation: implications for VTE prevention and bleeding among 1514 patients undergoing hematopoietic stem cell The incidence of and risk factors for venous thromboembolism (VTE) (2013) (1)
- Infusion of Donor Lymphocytes Specifically Directed to Multiple Tumor Antigens for the Treatment of High Risk Patients after HCT (2017) (1)
- Tumor Antigen Vaccination of Donors to Augment Graft-Versus-Tumor Effects after Allogeneic Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide (2016) (1)
- Allogeneic bone marrow transplantation (ALLO BMT): Role of t cell depletion (TCD) and graft versus host disease (GVHD) (2000) (1)
- Outcomes Of Allogeneic Blood Or Marrow Transplantation (AlloBMT) In Multiple Myeloma With Post-Transplantation Cyclophosphamide (PTCy) (2013) (1)
- Post-Transplant Cyclophosphamide (PT/Cy) Preserves Effector (Teff) and Regulatory (Treg) T Cells During Early Immune Reconstitution After Allogeneic Bone Marrow Transplantation (2012) (1)
- Secondary Systemic Immunosuppressants (SSI) After Myeloablative HLA Matched Related And Unrelated Bone Marrow Transplantation (BMT) Using High Dose Cyclophosphamide (HiCy) As Sole GVHD Prophylaxis (2010) (1)
- CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine. (2022) (1)
- Large Granular Lymphocytosis With Cytopenias After Allogeneic Blood or Marrow Transplantation: Clinical Characteristics and Response to Immunosuppressive Therapy. (2021) (1)
- Prophylaxis of Graft-Versus-Host Disease (GVHD) with Pentostatin, Tacrolimus, and “Mini”-Methotrexate (MTX): A Phase I/II Controlled, Randomized Study in Unrelated Donor (UD) Transplantation. (2007) (1)
- RAR-Alpha Targeting Compounds Overcome Bone Marrow (BM) Stromal Protection of AML By CYP26 (2015) (1)
- The next horizon now that everyone has a donor: Precision allogeneic transplantation. (2022) (1)
- 96: Incidence and Factors Influencing Stem Cell Mobilization in Patients with Non-Hodgkin's Lymphoma (NHL) and Hodgkin's Disease (HD) (2008) (1)
- Combination Therapy with Entinostat (MS-275) and GM-CSF to Enhance Differentiation In Myeloid Malignancies (2010) (1)
- Nonmyeloablative Allogeneic (Allo) BMT for B-Cell Lymphoma with Posttransplant Rituximab: Donor Selection by Prioritizing FCGR3A-158 Polymorphism Over HLA Matching. (2012) (1)
- The Fountain of Youth: Outcomes of Nonmyeloablative (NMA), HLA-Haploidentical Related (Haplo) Bone Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Best with Younger Donors Regardless of Relationship to Patient (2017) (1)
- Analysis of the Vβ T‐Cell Receptor Repertoire in Autologous Graft‐versus‐Host Disease a (1995) (1)
- Mismatched donor transplantation with post-transplantation cyclophosphamide for advanced cutaneous T-cell lymphoma: a single-center retrospective study (2022) (1)
- Cancer Stem Cell Principles (2015) (1)
- The Cell of Origin in NPM1 Positive Acute Myeloid Leukemia (AML) Is Prognostic (2016) (1)
- A refined risk score for acute GVHD that predicts response to initial therapy, survival and transplant-related mortality (2015) (1)
- Chronic Myeloid Leukemia Stem Cells and Their Differentiated Progeny Display Divergent Drug Sensitivities to Imatinib Mesylate and Interferon-Alpha. (2004) (1)
- Rapid Reconstitution Of The Regulatory T Cell Compartment After High Dose Cyclophosphamide Immunosuppression Prevents The Development Of GVHD After Allogeneic BMT (2010) (1)
- The novel telomerase inhibitor GRN163L targets drug-resistant cancer stem cells in multiple myeloma (2007) (1)
- The Use Of Donor Lymphocyte Infusion (DLI) For Relapse After Related T-Cell Replete HLA-Haploidentical Bone Marrow Transplantation (haploBMT) With Posttransplantation Cyclophosphamide (PTCy) (2013) (1)
- Abstract 4842: The stem cell niche detoxifies chemotherapy and protects malignant hematopoietic cells via expression of cytochrome P450 enzymes (2014) (1)
- Incidence of posttransplantation lymphoproliferative disorder (PTLD) following allogeneic blood or marrow transplantation (alloBMT) using post-transplantation cyclophosphamide (PT-Cy) for graft-versus-host disease (GVHD) prophylaxis. (2013) (1)
- Survival after autologous versus allogeneic transplantation in patients with relapsed and refractory Hodgkin lymphoma (2021) (1)
- 371: Altered gene expressions in human myeloid leukemia cells resistant to busulfan (2007) (0)
- Erratum: The novel anti-cancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1 (Journal of Pharmacology and Experimental Therapeutics (2013) 346 (381-392)) (2013) (0)
- Advances in Brief Cytotoxic T Cells Overcome BCR-ABL-mediated Resistance to Apoptosis 1 (2006) (0)
- Tumor and Stem Cell Biology Ex Vivo Graft Purging and Expansion of Autologous Blood Progenitor Cell Products from Patients with Multiple Myeloma (2011) (0)
- Increasing the dose of total body irradiation to decrease graft failure associated with HLA-haploidenticaltransplantation for patients with severe hemoglobinopathies. A single institution prospective clinical trial (2019) (0)
- The Art of Donor Selection: Donor Age and Relationship in NMA Haplo BMT (2021) (0)
- Grade II Acute Gvhd Improves Progression-Free Survival after Myeloablative HLA-Matched Bone Marrow Transplant with Posttransplantation Cyclophosphamide (2017) (0)
- GPI-Anchored Protein Deficiency Confers Resistance to Apoptosis in PNH. (2008) (0)
- Cytotoxic T Cells Overcome BCR-ABL-mediated Resistance to Apoptosis1 (2006) (0)
- Post-Transplantation Cyclophosphamide (PTCy) Based Graft Versus Host Disease (GVHD) Prophylaxis in Patients Undergoing Allogeneic Blood or Marrow Transplantation (BMT) for Myelofibrosis (MF) (2021) (0)
- Risk Factors for Graft-Versus-Host Disease after HLA-Haploidentical Transplantation with Posttransplantation Cyclophosphamide (2016) (0)
- Ovarian Carcinoma Stem Cells (2009) (0)
- 151: Mechanism of Busulfan Resistance of Myeloid Leukemia Cells (2008) (0)
- Graft-versus-Host Disease : The Pesky Fly in the Ointment (2007) (0)
- In utero hematopoietic stem cell transplantation in canines: The gestational window of opportunity to maximize engraftment (2005) (0)
- MYELOID NEOPLASIA All- trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD 1 leukemia stem cells in vitro and in vivo (2016) (0)
- Outcomes of Patients with TP53-Mutated Myeloid Neoplasms (TP53-MN) and the Role of Allogenic Blood or Marrow Transplantation (alloBMT) (2022) (0)
- IGHV Mutational Status Is Prognostic in Del(11q) and Del(17p) Chronic Lymphocytic Leukemia (2011) (0)
- Transplant Outcomes for IDH-Mutated AML: Good Outcomes Thanks to Keeping Good Company (2020) (0)
- Cancer Inhibition of Apoptosis during Development of Colorectal Updated (2006) (0)
- Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC) (2022) (0)
- Co-transducing B7H3 CAR-NK cells with the DNR preserves their cytolytic function against GBM in the presence of exogenous TGF-β (2022) (0)
- The Presence of SETBP1, RUNX1 or EZH2 Mutation in MDS/MPN Is Associated with Absence of Response to Hypo-Methylating Agents (2021) (0)
- High-dose cyclophosphamide for treatment of aplastic anemia. Authors' reply (2002) (0)
- Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab (2021) (0)
- Alternative donor BMT with post-transplant cyclophosphamide as initial therapy for acquired severe aplastic anemia. (2023) (0)
- Alternative Bone Marrow Transplantation with Post-Transplant Cyclophosphamide (PTCy) As Initial Therapy for Acquired Severe Aplastic Anemia (SAA) (2022) (0)
- Early Results Using Donor-Derived Marrow Infiltrating Lymphocytes (ddMILs) for Relapsed Disease after Allografting with Post-Transplant Cyclophosphamide (PTCy) (2019) (0)
- Allogeneic Blood or Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Based Graft Versus Host Disease (GVHD) Prophylaxis for Myelodysplastic Syndrome/ Myeloproliferative Neoplasm-Overlap Syndromes (MDS/MPN) (2020) (0)
- The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia (2022) (0)
- Abstract NT-107: CHEMORESISTANT OVARIAN CANCER STEM CELLS REVEAL NOVEL THERAPEUTIC TARGETS (2019) (0)
- Hematopoietic Cell Transplantation (HCT) Predictions for the Year 2023 (2020) (0)
- All-Trans Retinoic Acid Synergizes With FLT3 Tyrosine Kinase Inhibition To Eliminate FLT3/ITD-Expressing Leukemia Cells (2013) (0)
- Translating Leukemia Stem Cells into the Clinic: Harmonizing the Heterogeneity (2016) (0)
- Dedication - George Wesley Santos (2000) (0)
- Low Incidence of Severe Mucositis After Myeloablative, HLA-Matched Bone Marrow Transplantation and High Dose, Post-Transplantation Cyclophosphamide (2011) (0)
- Apoptosis Cytotoxic T Cells Overcome BCR-ABL-mediated Resistance to Updated Version (2006) (0)
- Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use (2020) (0)
- In utero hematopoietic stem cell transplantation: Rationale for continued work toward human application (2004) (0)
- Reduced Intensity Conditioned (RIC), HLA-haploidentical BMT in AML (2015) (0)
- Cytochrome P450 and drug metabolism in the stem cell niche (2015) (0)
- Allogeneic Transplantation in Septuagenarians Using Post-Transplant Cyclophosphamide (PTCy): Similar Outcomes to Younger Patients Except for Higher Late Non-Relapse Mortality (NRM) (2019) (0)
- Nonmyeloablative Haploidentical BMT with Post-Transplant Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies (2016) (0)
- Outcome of Donor-Derived Tumor Associated Antigen-Specific T Cell Therapy in Patients with High-Risk or Relapsed Acute Leukemia Post Allogeneic BMT (2021) (0)
- Abstract P2-07-04: Relevance of Mutated PIK3CA to Normal Mammary Gland Development and Malignancy (2010) (0)
- Abstract 5435: CCRL2 affects the sensitivity of MDS and secondary AML to azacitidine (2022) (0)
- MI-Immune/1801: Lessons from an Ongoing, Multi-Center Trial Involving Biospecimen Collection for Prospective Microbiome and Immune Profiling in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT (2021) (0)
- Long-Term R esults o f B lood a nd M arrow T ransplantation for H odgkin's L ymphoma (2001) (0)
- CX-5461, a Novel RNA Polymerase I Inhibitor, Is Active Against Wild-Type and Mutant p53 Myeloma Models (2013) (0)
- Correlation of acute myeloid leukemia (AML) stem cell phenotype with cytogenetic/molecular features and prognosis. (2015) (0)
- Hematopoietic Stem Cell Biology (2019) (0)
- Drug Resistance to the HDM-2 Inhibitors MI-63 and Nutlin Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA (2011) (0)
- Targeting the Human Double Minute (HDM)-2 p53 Ubiquitin Ligase as a Strategy Against Non-Hodgkin Lymphoma. (2007) (0)
- The development of post-transplant cyclophosphamide: Half a century of translational team science. (2022) (0)
- Methodology for radiobiological optimization of combination radiopharmaceutical therapy (RPT) (2013) (0)
- A phase II study of bexarotene + GM-CSF in refractory AML and high risk MDS. (2015) (0)
- Role of Cytochrome P450 Enzymes in the Maintenance of Breast Cancer Metastasized to the Bone [30D] (2019) (0)
- Allogeneic Bone Marrow Transplant for HIV Patients with Hematologic Malignancies with Post-transplant Cyclophosphamide: a Feasibility Study (2020) (0)
- Haploidentical BMT Using Fully Myeloablative Conditioning, T Cell Replete Grafts, and Post-Transplant Cyclophosphamide (PT/Cy) Has Limited Toxicity and Promising Efficacy in Pediatric Patients with High Risk Hematologic Malignanices (2013) (0)
- Protein Homeostatic Modulators, a Novel Class of Cereblon-Targeting Small Molecules As Potential Clinical Candidates in Multiple Myeloma (2017) (0)
- CCRL2 Promotes Cytokine-Regulated Growth of Erythroleukemia Cells (2022) (0)
- List of Contributors (2020) (0)
- 277: A Prospective Evaluation of the Effect of Polyoma (BK) Virus Infection on the Incidence of Hemorrhagic Cystitis (HC) after Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation (UD HSCT) (2008) (0)
- Acquired Aplastic Anemia (2020) (0)
- Response: Hodgkin lymphoma stem cells (2009) (0)
- Targeting the human double minute (HDM)-2 ubiquitin ligase as a strategy against non-Hodgkin’s lymphoma (2007) (0)
- multiple myeloma through a novel link between autophagy and apoptosis A Bim-targeting strategy overcomes adaptive bortezomib-resistance in (2014) (0)
- Preclinical Study of Combination of Antifolate Agents with Palbociclib Isethionate to Treat Mantle Cell Lymphoma with or without P53 Deficiency (2016) (0)
- Microchimerism following canine in utero hematopoietic stem cell transplantation: Development of T-cell dosing regimens (2004) (0)
- Risks and Outcomes of Cytokine Release in Haploidentical Peripheral Blood Stem Cell Transplantation (2018) (0)
- Properties , and Drug Resistance Clonogenic Multiple Myeloma Progenitors , Stem Cell (2007) (0)
- The Use of Post-Transplantation Cyclophosphamide after Myeloablative, HLA-Matched Allogeneic Bone Marrow Transplantation Minimizes the Need for Additional Immunosuppression (2016) (0)
- Posttransplant Cyclophosphamide-Based Transplantation from Haploidentical Donors Has Similar Outcomes As Unrelated Donor Transplantation in Myelofibrosis: A Center for International BMT Research (CIBMTR) Study (2023) (0)
- Requirement and Plasticity of CD4+Foxp3+ T Regulatory Cells (Tregs) in GVHD Prevention With High-Dose Posttransplant Cyclophosphamide (HiCy) in Mice and Humans (2011) (0)
- Efficacy of a Brief, Cyclophosphamide-Intensive Regimen for Older Patients with Newly Diagnosed Burkitt's or Atypical Burkitt's Lymphoma/Leukemia. (2009) (0)
- Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL (2020) (0)
- Myeloablative Allogeneic Bone Marrow Transplantation (AlloBMT) with T Cell Depletion (TCD) and Post-Transplant GM-CSF for Patients with High Risk MDS. (2006) (0)
- Treatment of Hepatitis-Associated Aplastic Anemia with High Dose Cyclophosphamide. (2006) (0)
- High Dose Cyclophosphamide (HD CY) without Hematopoietic Stem Cell Transplantation (HSCT) in Refractory Severe Autoimmune Diseases: 11 Year Experience in Over 100 Patients. (2009) (0)
- Reduced Intensity Conditioning Substituting Pentostatin for Fludarabine in Allogeneic Blood and Marrow Transplantation (AlloBMT) Is Safe and Effective (2023) (0)
- of graft-versus-host disease High-dose cyclophosphamide as single-agent, short-course prophylaxis (2013) (0)
- A pilot study CD34 selected haploidentical transplant using a chemotherapy-only preparative regimen and intensive antibiotic prophylaxis for treatment of advanced leukemia (2007) (0)
- Allogeneic Blood or Marrow Transplantation (alloBMT) Using Haploidentical Grandchildren Donors and Post-Transplant Cyclophosphamide (PTCy) -Based Gvhd Prophylaxis (2022) (0)
- Anti-Leukemic Effect of Maintenance Chemotherapy Is Mediated by Induction of Differentiation. (2005) (0)
- Second Blood or Marrow Transplant (BMT) for Relapse: Mismatch Haplotype Switch May Improve Outcome (2016) (0)
- Cost efficacy of PET/CT versus CT in relapsed diffuse large B-cell lymphoma (2008) (0)
- Kanakry Resistance to Posttransplantation Cyclophosphamide Aldehyde Dehydrogenase Expression Drives Human Regulatory T Cell (2013) (0)
- Clonality is an early event in aplastic anemia (AA) (2000) (0)
- Targeting Ovarian Carcinoma Stem Cells (2012) (0)
- Cell-Free DNA (cfDNA)-Based Measurable Residual Disease (MRD) Detection As a Predictor of Relapse Post-Allogeneic Blood or Marrow Transplant (alloBMT) in Patients with Myeloid Malignancies (2022) (0)
- Defining An Optimal Therapeutic Range for Busulfan (Bu) Administered with Pre-and Post-Transplant Cyclophosphamide (Cy) In HLA-Matched Related and Unrelated Bone Marrow Transplantation (BMT). (2010) (0)
- Incidence and Outcomes of Respiratory Failure After Non-Myeloablative Related Haploidentical Blood or Marrow Transplant (2021) (0)
- Intravenous Immunoglobulin G (IVIg) Suppresses HSP70-1 and Has Potential Therapeutic Effects Against Multiple Myeloma and Lymphoma (2013) (0)
- 297: Salvage Transplantation for Allograft Failure Utilizing Fludarabine and Alemtuzumab as the Conditioning Regimen (2008) (0)
- Sequential Flavopiridol , CytosineArabinoside , andMitoxantrone : APhase II Trial in Adults with Poor-Risk Acute Myelogenous Leukemia (2007) (0)
- Fludarabine, Melphalan and Thiotepa Conditioning for Unrelated Donor Cord Blood Transplantation (2009) (0)
- Inhibition of the HDM-2 E3 Ligase Induces Types I and II Cell Death in Wild-Type and Mutant p53 Models of Multiple Myeloma, and Acts Synergistically in Both with ABT-737. (2012) (0)
- A clinically relevant population of leukemic CD34 (cid:1) CD38 (cid:2) cells in acute myeloid leukemia (2012) (0)
- Abstract A50: Epstein-Barr virus in the putative stem cell fraction of some multiple myeloma cell lines. (2013) (0)
- Low Incidence of CMV Reactivation and Infectious Morbidity and Mortality after Nonmyeloablative Haploidentical Bone Marrow Transplantation Incorporating Post-Transplantation Cyclophosphamide. (2005) (0)
- Hematopoietic Stem Cell (HSC) Self-Renewal Is Determined by the Bone Marrow (BM) Microenvironment's Regulation of Retinoic Acid (RA) Signaling. (2012) (0)
- Abstract 1351: Post-transplantation cyclophosphamide depletes vaccine primed donor T cells and compromises graft-versus-tumor effects in alloBMT model (2015) (0)
- Comparison of Busulfan + Melphalan to Melphalan 200 mg/m2 as Preparative Regimen for Autologous Transplantation in Multiple Myeloma (2012) (0)
- High-Dose Cyclophosphamide for Treatment of Aplastic Anemia (2002) (0)
- Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers (2022) (0)
- Bone marrow niche chemoprotection of metastatic solid tumors mediated by CYP3A4. (2023) (0)
- IgVH Mutational Status Is Prognostic In 13q Deletion (del) Chronic Lymphocytic Leukemia (CLL) (2010) (0)
- A Quick, Robust Protocol for Liver Iron Quantitation on 3.0 Tesla MRI Scanners (2014) (0)
- Is post-transplant cyclophosphamide a true game-changer in allogeneic transplantation: The struggle to unlearn. (2019) (0)
- ~a~r~opl~~ in a woman with chronic hepatitis C infkction (2000) (0)
- Alternative Reduced Intensity Conditioning for Allogeneic Blood and Marrow Transplantation Using Pentostatin, Cyclophosphamide, and Total-Body Irradiation with Post-Transplant Cyclophosphamide (2022) (0)
- Burst-Forming Unit-Erythroid Assays (BFU-E) Can Help Distinguish Cellular Bone Marrow Failure Disorders (2012) (0)
- Extended Follow-up of Myeloablative, HLA-Matched Allogeneic BMT with High-Dose, Post-Transplantation Cyclophosphamide (PTCy) As Sole GVHD Prophylaxis: Favorable Outcomes Despite Low Incidence of Chronic GVHD (2014) (0)
- Prevention of graft versus host disease with Hematopoietic CellTransplantation with Reduced Intensity Conditioning—a comparison of threeprophylaxis regimens (tacrolimus/mycophenolate mofetil/cyclophosphamide,tacrolimus/methotrexate/bortezomib or tacrolimus/methotrexate/maraviroc) versustacrolimus/me (2019) (0)
- Haplo-Identical Bone Marrow Transplant Protocol using Reduced Intensity Conditioning for Fundeni Clinical Institute (2015) (0)
- Allogeneic Blood or Marrow Transplantation with Post-transplantation Cyclophosphamide for Peripheral T-cell Lymphoma: The Importance of Graft Source. (2022) (0)
- Low Incidence of CMV Reactivation and Infection after Allogeneic Bone Marrow Transplantation (BMT) Incorporating Post-Transplantation Cyclophosphamide (Cy). (2006) (0)
- Granulocyte-macrophage colony stimulating factor (GM-CSF, sargramostim/immunex corp.) after tcell- depleted allogeneic bmt for myelodysplastic syndromes (MDS): preliminary results of a phase ii trial (2000) (0)
- A Refined Clinical Risk Score at Onset of Treatment for Acute Gvhd That Predicts Response to Initial Therapy, Survival and Transplant-Related Mortality (2014) (0)
- Allogeneic Blood or Marrow Transplant for Older Patients: An Analysis of Physiologic Variables (2021) (0)
- Thalidomide , and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle Through Phosphoinositide 3-kinase Signaling and Ikaros Expression Running title : Immunomodulatory drugs reactivate lytic EBV (2016) (0)
- Assessing Early Supportive Care Needs Among Son or Daughter Haploidentical Transplantation Donors. (2020) (0)
- Allogeneic Blood or Marrow Transplantation with High-Dose Post-transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Aged ≥55. (2022) (0)
- Abstract B15: Targeting SQSTM1/p62 induces cargo-loading failure and converts autophagy to apoptosis via NBK/Bik in human multiple myeloma cells. (2015) (0)
- Pretransplant conditioning with IV busulfan (Bu) and fludarabine (Flu) as alternative to Bu and cyclophosphamide (Cy)—a safe, myeloablative regimen with high antileukemic efficacy in AML/MDS (2005) (0)
- Granulocyte-macrophage colony stimulating factor (GM-CSF, sargramostim/immunex corp.) after tcell- depleted allogeneic bmt for myelodysplastic syndromes (MDS) (2000) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Richard Julian Jones?
Richard Julian Jones is affiliated with the following schools:
